August 22-29, 2022: Other News on the Web
Every week, there are so many important and interesting articles related to the care of women. While these articles may not fall under the umbrella of reproductive psychiatry, much of this information affects the women we care for.
FDA Accepts New Drug Application for Fezolinetant, A Novel Nonhormonal Treatment for Vasomotor Symptoms
The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.
Essential Reads: Folic Acid, Neural Tube Defects, and Congenital Heart Defects
Despite the unequivocal benefits of folic acid supplementation and recommendations urging all women of reproductive age to take folic acid supplements, preconceptual use of folic acid has not increased substantially.
Seeking stories from survivors, family members, and clinicians who have grappled with PPD.
Interested in participating in future research at the CWMH? You are invited to complete our interest form.
- Preventing depressive relapse in pregnancy and the postpartum
PMS & PMDD
When PMS symptoms interfere with functioning and quality of life
Fertility & Mental Health
Stress, depression, and anxiety associated with infertility and its treatment
Perinatal Substance Use
How can we best address substance use in women of reproductive age?
Menopausal Symptoms
Depression, hot flashes, sleep disturbance… What are safe treatment for symptomatic midlife women?
Psychiatric Disorders During Pregnancy
Weighing the risks and benefits of pharmacologic treatment during pregnancy
Breastfeeding & Psychiatric Medications
How safe is it for women to take medications and breastfeed?
Postpartum Psychiatric Disorders
Most women suffering from postpartum depression do not receive adequate care
